Form 4 for PBYI PUMA BIOTECHNOLOGY, INC.
Accepted 2026-07-08 20:21:27 ET · period of report 2026-07-06 · accession 0001437749-26-023079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-07-08 20:21 | 2026-07-06 | PBYI | AUERBACH ALAN H | Pres, CEO, Dir, 10% | S - Sale | $8.26 | -44.1K | 7.26M | -0.6% | -$364.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-06 | S | D | 44,058 | $8.26 | 7,261,671 | D | — | — | (F1) Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. |